文献速递肝病

欧洲慢加急性肝衰竭患者肝移植的ELITA/EF-CLIF协作研究(ECLIS)

Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS).
PubMed 文献 · J Hepatol · 2021-05-02

该回顾性研究纳入欧洲8国20中心308例连续登记的ACLF等待肝移植患者,评估当前临床实践与结局。2018年1月至2019年6月期间共2677例接受肝移植,其中234例(19.2%)移植时有ACLF,移植后1年生存概率81%(95%CI 74-87),但各国ACLF-2/3移植率差异显著(3%-41%)。

要点

  • ACLF患者肝移植后1年生存概率为81%(95%CI 74-87)。
  • 移植前动脉乳酸>4 mmol/L、近期耐多药菌感染和肾脏替代治疗是移植后死亡的独立预测因素。
  • 等待名单上ACLF-1或-2患者1年生存率73%,ACLF-3为50%(意向性治疗分析)。

核心结论

  • 欧洲ACLF患者肝移植后生存率良好,但各国等待名单登记存在显著差异,需协调以促进公平。
  • 已识别移植后死亡风险因素,有助于更精确的预后评估。

研究设计与样本

  • 回顾性研究,纳入2018年1月至2019年6月欧洲8国20中心308例连续登记的ACLF等待肝移植患者。

主要发现

  • 共2677例接受肝移植,其中1216例(45.4%)为失代偿肝硬化;234例(19.2%)移植时有ACLF:ACLF-1 58例(4.8%)、ACLF-2 78例(6.4%)、ACLF-3 98例(8.1%)。
  • 各国ACLF-2/3移植率差异显著:法国和德国为27-41%,意大利、瑞士、波兰和荷兰为9-15%,英国和西班牙为3-5%(p<0.0001)。
  • 移植前动脉乳酸>4 mmol/L(HR 3.14;95%CI 1.37-7.19)、近期耐多药菌感染(HR 3.67;95%CI 1.63-8.28)和肾脏替代治疗(HR 2.74;95%CI 1.37-5.51)是移植后死亡的独立预测因素。
  • 同期74例ACLF患者在等待名单上死亡;意向性治疗分析中,等待名单上ACLF-1或-2患者1年生存率73%,ACLF-3为50%。

关键数值与推荐

  • 移植后1年生存概率81%(95%CI 74-87)。
  • 移植前动脉乳酸>4 mmol/L:HR 3.14(95%CI 1.37-7.19)。
  • 近期耐多药菌感染:HR 3.67(95%CI 1.63-8.28)。
  • 肾脏替代治疗:HR 2.74(95%CI 1.37-5.51)。

临床怎么用

  • ACLF患者可考虑肝移植作为挽救性治疗,移植后1年生存率可达81%。
  • 移植前评估应关注动脉乳酸水平、近期耐多药菌感染和肾脏替代治疗需求,以识别高风险患者。
  • 欧洲各国ACLF患者肝移植登记实践差异大,需协调转诊和准入以减少不公平。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver transplantation (LT) has been proposed as an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was designed to assess the current clinical practice and outcomes of patients with ACLF who are wait-listed for LT in Europe. METHODS: This was a retrospective study including 308 consecutive patients with ACLF, listed in 20 centres across 8 European countries, from January 2018 to June 2019. RESULTS: A total of 2,677 patients received a LT: 1,216 (45.4%) for decompensated cirrhosis. Of these, 234 (19.2%) had ACLF at LT: 58 (4.8%) had ACLF-1, 78 (6.4%) had ACLF-2, and 98 (8.1%) had ACLF-3. Wide variations were observed amongst countries: France and Germany had high rates of ACLF-2/3 (27-41%); Italy, Switzerland, Poland and the Netherlands had medium rates (9-15%); and the United Kingdom and Spain had low rates (3-5%) (p <0.0001). The 1-year probability of survival after LT for patients with ACLF was 81% (95% CI 74-87). Pre-LT arterial lactate levels >4 mmol/L (hazard ratio [HR] 3.14; 95% CI 1.37-7.19), recent infection from multidrug resistant organisms (HR 3.67; 95% CI 1.63-8.28), and renal replacement therapy (HR 2.74; 95% CI 1.37-5.51) were independent predictors of post-LT mortality. During the same period, 74 patients with ACLF died on the waiting list. In an intention-to-treat analysis, 1-year survival of patients with ACLF on the LT waiting list was 73% for ACLF-1 or -2 and 50% for ACLF-3. CONCLUSION: The results reveal wide variations in the listing of patients with ACLF in Europe despite favourable post-LT survival. Risk factors for mortality were identified, enabling a more precise prognostic assessment of patients with ACLF. LAY SUMMARY: Acute-on-chronic liver failure (ACLF) is a severe clinical condition for which liver transplantation is an effective therapeutic option. This study has demonstrated that in Europe, referral and access to liver transplantation (LT) for patients with ACLF needs to be harmonised to avoid inequities. Post-LT survival for patients with ACLF was >80% after 1 year and some factors have been identified to help select patients with favourable outcomes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Belli LS, Duvoux C, Artzner T, et al. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021. PMID: 33951535. doi:10.1016/j.jhep.2021.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。